Can afatinib (Giteri) be taken separately and what precautions should be taken?

Afatinib (Afatinib) is an oral irreversible EGFRtyrosine kinase inhibitor, mainly used to treat patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Regarding whether it can be taken in pieces, afatinib is generally taken as a whole capsule or tablet, and it is not recommended to break or chew it without authorization. The reason is that the drug is designed with sustained release and stability in mind. Once the tablet structure is broken or damaged, it may cause uneven drug absorption or increase blood concentration, thereby increasing the risk of adverse reactions.

In clinical practice, if the patient does have difficulty swallowing, he or she can consult the doctor or pharmacist whether there are other dosage forms or dissolvable preparations that can be substituted. Currently, afatinib on the market is mainly in the form of a whole tablet for oral administration, so it is necessary to follow the doctor's medication instructions to ensure the efficacy and safety of the drug. At the same time, patients should take the drug at a fixed time, usually once a day, on an empty stomach or with a certain interval between food and drink to optimize drug absorption.

Common side effects such as diarrhea, rash, stomatitis, or abnormal liver function may occur while taking afatinib. If you break the tablets without permission, the blood concentration may increase for a short time, aggravating these side effects. Especially for elderly patients or those with abnormal renal function, it is necessary to strictly follow the principle of taking the whole tablet. At the same time, blood routine, liver and kidney function, blood pressure and other indicators should be regularly monitored during medication so that adverse reactions can be detected in a timely manner and dosage adjustments can be made.

In order to ensure medication safety, patients should avoid changing the dosage or damaging the tablet structure when taking afatinib. If there are special circumstances, they should consult their attending physician as soon as possible. Maintaining good medication habits, regular follow-up and monitoring will not only help achieve the best efficacy, but also reduce the risk of serious side effects, providing a stable and safe targeted therapy for patients with EGFR mutation-positive non-small cell lung cancer.

Reference materials:https://www.drugs.com/